Saskia Herges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saskia Herges has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Florian Sänger
Ludwig-Maximilians-Universität Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
2 shared publications - René Dörfelt
Ludwig-Maximilians-Universität Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
2 shared publications Hannah Ohrem
LMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication- Katrin Hartmann
LMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, LMU Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Hemoadsorption with the Cytosorb adsorber can effectively reduce cell-free hemoglobin from porcine blood in vitro
Objective: The aim of this study was to investigate the maximum capacity of the Cytosorb adsorber for clearance of cell-free hemoglobin (cfHb) in a porcine cfHb solution in vitro. Methods: Anticoagulated porcine blood was centrifuged to separate plasma from RBCs. Red blood cell concentrate was stored in the freezer, thawed, and mixed with distilled water to achieve complete hemolysis. The cfHb solution was divided into 12 aliquots of 1,000 mL each. Six test runs were performed in a circular setup with the Cytosorb adsorber. Samples were collected before and after adsorber. After 20 L of processed cfHb solution, the storage bottle was exchanged, and a new storage bottle with 1,000 mL of the cfHb solution with the initial cfHb concentration was processed for another 10 L. Results: The initial median cfHb concentration of the porcine cfHb solution of 4.13 mmol/L (4.03 to 4.22 mmol/L) decreased to 2.70 mmol/L (2.54 to 2.79 mmol/L) after processing 20 L of cfHb solution. This corresponds to a median cfHb reduction of 22.1 g (21.9 to 27.1 g), which was primarily achieved during the first 10.0 L of processed cfHb solution. In the second storage bottle, no further relevant cfHb concentration decrease was achieved. Conclusions: Hemoadsorption using the Cytosorb adsorber effectively reduced cfHb concentration from a porcine cfHb solution in vitro. The maximum adsorption capacity of the Cytosorb adsorber for this experimental setup was about 22.1 g. Clinical Relevance: The Cytosorb adsorber might be a promising tool for removal of cfHb from the circulation in vivo.
- 24 September 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Open AccessHemoadsorption with the Cytosorb adsorber can effectively reduce cell-free hemoglobin from porcine blood in vitro
Objective: The aim of this study was to investigate the maximum capacity of the Cytosorb adsorber for clearance of cell-free hemoglobin (cfHb) in a porcine cfHb solution in vitro. Methods: Anticoagulated porcine blood was centrifuged to separate plasma from RBCs. Red blood cell concentrate was stored in the freezer, thawed, and mixed with distilled water to achieve complete hemolysis. The cfHb solution was divided into 12 aliquots of 1,000 mL each. Six test runs were performed in a circular setup with the Cytosorb adsorber. Samples were collected before and after adsorber. After 20 L of processed cfHb solution, the storage bottle was exchanged, and a new storage bottle with 1,000 mL of the cfHb solution with the initial cfHb concentration was processed for another 10 L. Results: The initial median cfHb concentration of the porcine cfHb solution of 4.13 mmol/L (4.03 to 4.22 mmol/L) decreased to 2.70 mmol/L (2.54 to 2.79 mmol/L) after processing 20 L of cfHb solution. This corresponds to a median cfHb reduction of 22.1 g (21.9 to 27.1 g), which was primarily achieved during the first 10.0 L of processed cfHb solution. In the second storage bottle, no further relevant cfHb concentration decrease was achieved. Conclusions: Hemoadsorption using the Cytosorb adsorber effectively reduced cfHb concentration from a porcine cfHb solution in vitro. The maximum adsorption capacity of the Cytosorb adsorber for this experimental setup was about 22.1 g. Clinical Relevance: The Cytosorb adsorber might be a promising tool for removal of cfHb from the circulation in vivo.
- Open Access
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Hematological changes after intermittent hemodialysis in dogs with acute kidney injury are mild and transient
Objective: To evaluate hematological changes in dogs with acute kidney injury caused by different underlying disease processes treated with intermittent hemodialysis (IHD) over 12 to 24 hours after the session. Methods: Client-owned dogs with acute kidney injury treated with IHD from February 2021 through July 2025 were prospectively enrolled in this observational study. Blood was collected from each dog before IHD (T0), after IHD (T1), and 12 to 24 hours after IHD (T2). Hematocrit, RBC count, hemoglobin concentration, reticulocyte count, platelet count, and WBC count were evaluated at all time points. Results: In total, 30 dogs with 82 IHD sessions were included in the study. Median RBC count (X 10 12 /L) and median hemoglobin concentration (mmol/L) decreased from 4.00 (2.82 to 7.22) and 9.25 (6.60 to 17.20) at T0 to 3.74 (2.39 to 7.04) and 9.00 (5.50 to 16.80) at T1, respectively. Median WBC count (X 10 9 /L) of 19.34 (6.49 to 55.47) at T0 decreased to 17.6 (4.57 to 73.22) at T1 and increased to 20.11 (7.48 to 55.47) at T2. Median platelet count (X 10 9 /L) of 99 (5 to 767) at T0 decreased to 69 (1 to 633) at T1 and increased to 84 (4 to 604) at T2. Conclusions: Hematological changes during IHD were mild and transient. Only the platelet count decreased moderately. Clinical Relevance: Most of the hematological changes did not appear clinically relevant and resolved within 24 hours. However, the moderate decrease in platelet count could potentially predispose dogs undergoing IHD to an increased risk of bleeding.
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Open AccessHematological changes after intermittent hemodialysis in dogs with acute kidney injury are mild and transient
Objective: To evaluate hematological changes in dogs with acute kidney injury caused by different underlying disease processes treated with intermittent hemodialysis (IHD) over 12 to 24 hours after the session. Methods: Client-owned dogs with acute kidney injury treated with IHD from February 2021 through July 2025 were prospectively enrolled in this observational study. Blood was collected from each dog before IHD (T0), after IHD (T1), and 12 to 24 hours after IHD (T2). Hematocrit, RBC count, hemoglobin concentration, reticulocyte count, platelet count, and WBC count were evaluated at all time points. Results: In total, 30 dogs with 82 IHD sessions were included in the study. Median RBC count (X 10 12 /L) and median hemoglobin concentration (mmol/L) decreased from 4.00 (2.82 to 7.22) and 9.25 (6.60 to 17.20) at T0 to 3.74 (2.39 to 7.04) and 9.00 (5.50 to 16.80) at T1, respectively. Median WBC count (X 10 9 /L) of 19.34 (6.49 to 55.47) at T0 decreased to 17.6 (4.57 to 73.22) at T1 and increased to 20.11 (7.48 to 55.47) at T2. Median platelet count (X 10 9 /L) of 99 (5 to 767) at T0 decreased to 69 (1 to 633) at T1 and increased to 84 (4 to 604) at T2. Conclusions: Hematological changes during IHD were mild and transient. Only the platelet count decreased moderately. Clinical Relevance: Most of the hematological changes did not appear clinically relevant and resolved within 24 hours. However, the moderate decrease in platelet count could potentially predispose dogs undergoing IHD to an increased risk of bleeding.